Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis

Abstract

Background The original non–vitamin K antagonist oral anticoagulant ( NOAC ) trials in nonvalvular atrial fibrillation ( AF ) enrolled patients with native valve pathologies. The object of this study was to quantify the benefit–risk profiles of NOAC s versus warfarin in AF patients with native valvular heart disease ( VHD ). Methods and Results Trials were identified by exhaustive literature search. Trial data were combined using inverse variance weighting to produce a meta‐analytic summary hazard ratio ( HR ) and 95% confidence interval ( CI ) of efficacy and safety of NOAC s versus warfarin. Our final analysis included 4 randomized controlled trials that enrolled 71 526 participants, including 13 574 with VHD . Pooling results from included trials showed that NOAC s versus warfarin reduced stroke or systemic embolism ( HR : 0.70; 95% CI , 0.60–0.82) and intracranial hemorrhage ( HR : 0.47; 95% CI , 0.24–0.92) in AF patients with VHD . However, risk reduction of major bleeding and intracranial hemorrhage was driven by apixaban, edoxaban, and dabigatran (HR for major bleeding: 0.79 [95% CI , 0.69–0.91]; HR for intracranial hemorrhage: 0.33 [95% CI , 0.25–0.45]) but not rivaroxaban (HR for major bleeding: 1.56 [95% CI , 1.20–2.04]; HR for intracranial hemorrhage: 1.27 [95% CI , 0.77–2.10]). Conclusions Among patients with AF and native VHD , NOAC s reduce stroke and systemic embolism compared with warfarin. Evidence shows that apixaban, dabigatran, and edoxaban also reduce bleeding in this patient subgroup, whereas major bleeding (but not intracranial hemorrhage or mortality rate) is significantly increased in VHD patients treated with rivaroxaban. NOAC s are a reasonable alternative to warfarin in AF patients with VHD .